Autifony Therapeutics initiates recruitment into schizophrenia clinical trial for first-in-class drug

Stevenage UK – 18 May 2017 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced the start of a Phase Ib biomarker study of the effect of AUT00206, a first-in-class Kv3 ion channel modulator, on patients with schizophrenia.

Read more (213 kB)